Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Insider Trading in U.S. Stocks | Madrigal disclosed 16 insider transactions on March 6
On March 6, 2026, Madrigal (MDGL) disclosed 16 insider trading transactions. Director Sibold William John sold 1,663 shares on March 6, 2026.
【Recent Insider Transactions】
【Company Profile】
Madrigal Pharmaceuticals, Inc. was founded in March 2000 and began operations in July 2001. The company is a biopharmaceutical firm focused on developing new treatments for fatty liver disease related to metabolic dysfunction. Fatty liver disease is a serious liver condition with high unmet medical needs, which can lead to cirrhosis, liver failure, cancer, liver transplant requirements, and premature death. The company’s drug Rezifra is an oral, once-daily liver-targeted thyroid hormone receptor beta agonist designed to address the key underlying causes of MASH.